ABIVAX vs Cytokinetics
ABIVAX (ABVX), health care, and Cytokinetics (CYTK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
ABIVAX and Cytokinetics are valued at about the same: $7.2B and $7.2B. Over the past year ABIVAX's share price has moved -26.5% and Cytokinetics's -19.6%.
Key facts
- ABIVAX market value
- $7.2B
- Cytokinetics market value
- $7.2B
- Cytokinetics revenue
- $88MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | ABIVAX | Cytokinetics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.2Blower | $7.2Bhigher |
| Revenue | — | $88M |
| Earnings | -$372.9Mhigher | -$785Mlower |
| Employees | 98lower | 673higher |
| Total assets | $648.3Mlower | $1.4Bhigher |
| Valuation | ||
| P/E | — | — |
| P/S | — | 81.7 |
| P/B | — | — |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | — | -695% |
| Balance sheet | ||
| Net assets | $505.1Mhigher | -$659.6Mlower |
| Total liabilities | $143.3Mlower | $2.1Bhigher |
| Total debt | — | $287.6M |
| Cash on hand | $573.3Mhigher | $122.5Mlower |
| Price change | ||
| Today | -1.81%higher | -2.86%lower |
| 1 year | -26.5%lower | -19.6%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
ABIVAX only (4)
- Peter Kolchinsky1.3%
- Doug Silverman0.4%
- Andrew Spokes0.1%
- Lee Ainslie<0.1%
Cytokinetics only (3)
- Brandon Haley0.2%
- Steve Cohen0.2%
- Julian and Felix Baker0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns ABVX · Who owns CYTK
More on ABIVAX
Further comparisons
ABIVAX against its closest peers
Cytokinetics against its closest peers
Learn
Questions and answers
Which is bigger, ABIVAX or Cytokinetics?
By market value, Cytokinetics is the larger: $7.2B against $7.2B for ABIVAX.
Which superinvestors own both ABIVAX and Cytokinetics?
None of the tracked superinvestors holds both in their latest 13F filing. 4 hold ABIVAX and 3 hold Cytokinetics.
Cite this page
Funkfolio, “ABIVAX vs Cytokinetics”, data as of 17 November 2026. https://funkfolio.com/compare/abvx-vs-cytk
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.